Antisoma, a biotechnology company specializing in the development of novel drugs for the treatment of cancer, released a statement that the vaccine ASA404 improves anticancer responses and survival for patients with non-small cell lung cancer.

ASA404 is known as a vascular disrupting agent (VDA). ASA404 is different from angiogenenesis inhibitors that disrupt the new formation of blood vessels. This vaccine disrupts established blood vessels that feed cancer cells.

The researchers concluded that ASA404 appears promising in the treatment of advanced non-small cell lung cancer. A Phase III clinical trial is expected to begin in 2008. This is the last step prior to FDA review.

A German biotech company has announced positive results from a genetically engineered herpes virus that is designed to kill cancer cells. It not only kills the cancer cells but leaves healthy tissue unharmed. Results from clinical trials has showed promise.

Being injected with a virus might seem strange but researchers believe that viruses could one day become a valuable addition to conventional cancer treatments.

The results have shown in animal testing and limited human testing the ability to kill colorectal and liver cancer cells.

I have been a cheerleader for the breast cancer drug Herceptin ever since I began receiving it. I had my initial worries -- about an allergic reaction that I knew caused death within 24 hours for a handful of women and about possible toxicity to the heart -- but after faring well through my first dose and having now successfully completed my one year obligation to the drug, with no allergic reaction or heart damage, I have come to believe the Herceptin might just be the gem of a drug that the media says it is. Yet now I've read an article that makes me question what I really know about Herceptin -- and the studies that surround it and the statistics that back it and the messages sent out over the lines of mass communication to every day, non-medical people like me.